Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filedfiledCritical
Priority to ECSP003493priorityCriticalpatent/ECSP003493A/en
Publication of ECSP003493ApublicationCriticalpatent/ECSP003493A/en
Esta invención se refiere a los profármacos mutuos de amlodipino y atorvastatina ya las composicones farmacéuticas de los mismos. Esta invención también se refiere a los procedimientos para tratar la angina de pecho, la aterosclerosis y la hipertensión y la hiperlipidemia en un mamífero mediante el uso de estos profármacos y composiciones. Esta invención también se refiere a los procedimientos para tratar el riesgo cardiaco en un mamífero, incluyendo humanos, se presentan síntomas de riesgo cardiaco mediante la administración de estos profármacos y composiciones.This invention relates to the mutual prodrugs of amlodipine and atorvastatin and the pharmaceutical compositions thereof. This invention also relates to methods for treating angina, atherosclerosis and hypertension and hyperlipidemia in a mammal by the use of these prodrugs and compositions. This invention also relates to methods for treating cardiac risk in a mammal, including humans, symptoms of cardiac risk are presented by administering these prodrugs and compositions.
ECSP0034932000-05-252000-05-25
MUTUAL PROPHARMACES OF AMLODIPINO AND ATORVASTATIN
ECSP003493A
(en)
PHARMACEUTICAL COMPOSITIONS, PHARMACEUTICAL COMPOSITIONS FOR USE WITH A SECOND COMPOSITION TO OBTAIN AN IMPROVEMENT IN THE THERAPEUTIC EFFECT, A KIT WHICH CONTAINS AND USE OF A COMPOUND TO PREPARE THE COMPOSITION
PHARMACEUTICAL COMPOSITIONS THAT INCLUDE A COMBINATION OF RAPAMYCIN OR ITS DERIVATIVE AND PIMECROLIMUS FOR THE TREATMENT OF INFLAMMATORY AND IMMUNOLOGICALLY MEDIATED DISEASES
EMPLOYMENT OF 2-6-AMINOTETRALINES APPROPRIATE SUBSTITUTES FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR THE THERAPEUTIC TREATMENT OF INFLAMMATORY AND / OR AUTOIMMUNE PATHOLOGIES.